<DOC>
	<DOCNO>NCT01036932</DOCNO>
	<brief_summary>The purpose study determine whether Granulocyte Colony Stimulating factor ( G-CSF ) therapy effective treatment patient Acute chronic liver failure ( ACLF ) . The investigator hypothesize ACLF disease severe hepatic impairment accompany impaired hepatic regeneration . BMC mobilization use G-CSF therapy , G-CSF therapy per se would increase regenerative capacity liver shall lead clinical , biochemical histological improvement patient ACLF .</brief_summary>
	<brief_title>Granulocyte Colony Stimulating Factor ( G-CSF ) Therapy Patients With ACLF</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients acute hepatic insult manifest jaundice ( Sr. Bil . ≥5 mg/dL ) coagulopathy ( INR≥1.5 ) , complicate within 4 week ascites and/or encephalopathy patient previously diagnose undiagnosed chronic liver disease . ( APASL criterion ) HCC portal vein thrombosis . Refusal participate study . Sepsis ( Any culture positive : blood , urine , focus infection Xray chest , obvious source infection : UTI , SBP ) Multi organ failure . Grade 3 4 hepatic encephalopathy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>